1. Home
  2. AAL vs TGTX Comparison

AAL vs TGTX Comparison

Compare AAL & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo American Airlines Group Inc.

AAL

American Airlines Group Inc.

N/A

Current Price

$13.79

Market Cap

9.6B

ML Signal

N/A

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

N/A

Current Price

$50.70

Market Cap

7.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AAL
TGTX
Founded
1930
1993
Country
United States
United States
Employees
133700
N/A
Industry
Air Freight/Delivery Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.6B
7.9B
IPO Year
2004
2008

Fundamental Metrics

Financial Performance
Metric
AAL
TGTX
Price
$13.79
$50.70
Analyst Decision
Buy
Strong Buy
Analyst Count
18
5
Target Price
$15.59
$49.80
AVG Volume (30 Days)
58.2M
2.2M
Earning Date
04-23-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
1746.67
EPS
N/A
0.17
Revenue
$54,633,000,000.00
$2,785,000.00
Revenue This Year
$12.17
$49.08
Revenue Next Year
$4.62
$26.69
P/E Ratio
N/A
$297.41
Revenue Growth
0.78
N/A
52 Week Low
$10.09
$26.76
52 Week High
$18.79
$59.30

Technical Indicators

Market Signals
Indicator
AAL
TGTX
Relative Strength Index (RSI) 36.19 55.26
Support Level $13.22 $51.22
Resistance Level $14.17 $58.08
Average True Range (ATR) 0.42 1.83
MACD -0.20 0.26
Stochastic Oscillator 8.02 93.86

Price Performance

Historical Comparison
AAL
TGTX

About AAL American Airlines Group Inc.

American Airlines is the world's largest airline by aircraft, capacity, and scheduled revenue passenger miles. Its major US hubs are Dallas/Fort Worth, Charlotte, Chicago, Los Angeles, Miami, New York, Philadelphia, Phoenix, and Washington, D.C. It generates over 30% of US airline revenue connecting Latin America with destinations in the United States. After completing a major fleet renewal, the company has the youngest average fleet of US legacy carriers.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: